drugset / Trial / NCT00077025

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

NCT00077025

Phase 2 Completed 174 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being carried out to see if treatment with ZD1839 (Gefitinib) combined with Arimidex (Anastrozole) has improved efficacy over Arimidex alone in preventing progression of metastatic breast cancer.

Timeline

Start
2004-01
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gefitinib Small molecule 250 mg Oral
Comparator Anastrozole Other / unclassified 1 mg Oral

Indications